Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Lancet Oncol. 2015 Jul 30;16(9):1025–1036. doi: 10.1016/S1470-2045(15)00201-6

Figure 1.

Figure 1

Figure 1

Figure 1

Figure 1

Overall survival (OS) in patients with relapsed and refractory acute myeloid leukaemia treated with vosaroxin or placebo in combination with cytarabine, for all patients (A), censored for allogeneic stem cell transplant (alloSCT) (B), patients aged ≥60 years vs <60 years (C, D); and early relapsed vs late relapsed vs refractory patients (E, F, G).

CI= confidence interval; HR=hazard ratio; Pla/Cyt=placebo+cytarabine; Vos/Cyt=vosaroxin+cytarabine.